First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience

Research output: Contribution to journalJournal articleResearchpeer-review

Ingrid Holst Olsen, Seppo W Langer, Ida Jepsen, Maria Assens, Birgitte Federspiel, Jane Preuss Hasselby, Carsten Palnaes Hansen, Andreas Kjaer, Ulrich Knigge

Poorly differentiated neuroendocrine carcinomas (PDECs) represent highly malignant tumors with an immense tendency to metastasize and with a poor prognosis. The treatment consists of palliative chemotherapy and corresponds to the treatment of extensive stage small cell lung cancer.
Original languageEnglish
JournalActa Oncologica
Issue number1
Pages (from-to)97-100
Number of pages4
Publication statusPublished - 2012

ID: 40171608